Chemours: Vanguard reports 0 shares in Schedule 13G/A
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Vanguard report for Chemours (CC) ownership in this amendment?
Why are Vanguard subsidiaries reporting separately for Chemours (CC)?
Who signed the Schedule 13G/A amendment for Vanguard on Chemours (CC)?
Does this amendment show any Vanguard voting or dispositive power for Chemours (CC)?
AI-generated analysis. How Rhea-AI works. Not financial advice.